Efficacy and safety profile of fexofenadine HCl: a unique therapeutic option in H1-receptor antagonist treatment - PubMed (original) (raw)

Review

Efficacy and safety profile of fexofenadine HCl: a unique therapeutic option in H1-receptor antagonist treatment

Suzanne G Meeves et al. J Allergy Clin Immunol. 2003 Oct.

Abstract

Results of head-to-head comparative trials suggest that fexo-fenadine might offer distinct advantages compared with other antihistamines. Fexofenadine is highly selective for peripheral H(1)-receptors and does not cross the blood-brain barrier, as shown by positron emission tomography. These data support findings that fexofenadine is nonsedating and does not impair performance or driving ability, even at very high doses. In addition, fexofenadine does not interact with muscarinic receptors, which might offer a potential advantage compared with desloratadine, the recently approved active metabolite of loratadine. Fexofenadine is devoid of adverse cardiac effects, and changes in electrocardiogram parameters are not significantly different from those observed with placebo. Fexofenadine has also been shown to have a favorable effect on nasal congestion. This therapeutic advantage might be related to its significant antiallergic properties, ie, the demonstrated ability of fexofenadine to blunt the inflammatory effects of preformed and de novo synthesized mediators at clinically relevant doses in vivo and in vitro. Cumulatively, these benefits distinguish fexofenadine from other antihistamines and make it an optimum therapeutic option for treating allergy-mediated respiratory and dermatologic diseases.

PubMed Disclaimer

Similar articles

• Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria.
  Simpson K, Jarvis B. Simpson K, et al. Drugs. 2000 Feb;59(2):301-21. doi: 10.2165/00003495-200059020-00020. Drugs. 2000. PMID: 10730552
• Safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis--a pooled analysis of three studies.
  Meltzer EO, Scheinmann P, Rosado Pinto JE, Bachert C, Hedlin G, Wahn U, Finn AF Jr, Ruuth E. Meltzer EO, et al. Pediatr Allergy Immunol. 2004 Jun;15(3):253-60. doi: 10.1111/j.1399-3038.2004.00167.x. Pediatr Allergy Immunol. 2004. PMID: 15209959 Clinical Trial.
• Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis.
  Howarth PH, Stern MA, Roi L, Reynolds R, Bousquet J. Howarth PH, et al. J Allergy Clin Immunol. 1999 Nov;104(5):927-33. doi: 10.1016/s0091-6749(99)70070-9. J Allergy Clin Immunol. 1999. PMID: 10550734 Clinical Trial.
• Effects of fexofenadine and other antihistamines on components of the allergic response: adhesion molecules.
  Ciprandi G, Tosca MA, Cosentino C, Riccio AM, Passalacqua G, Canonica GW. Ciprandi G, et al. J Allergy Clin Immunol. 2003 Oct;112(4 Suppl):S78-82. doi: 10.1016/s0091-6749(03)01880-3. J Allergy Clin Immunol. 2003. PMID: 14530792 Review.

Cited by

• Effects of single therapeutic doses of promethazine, fexofenadine and olopatadine on psychomotor function and histamine-induced wheal- and flare-responses: a randomized double-blind, placebo-controlled study in healthy volunteers.
  Kamei H, Isaji A, Noda Y, Ishikawa K, Senzaki K, Yamada K, Sugiura K, Tomita Y, Nabeshima T. Kamei H, et al. Arch Dermatol Res. 2012 May;304(4):263-72. doi: 10.1007/s00403-011-1192-2. Epub 2011 Dec 1. Arch Dermatol Res. 2012. PMID: 22130869 Free PMC article. Clinical Trial.
• False Positive Tramadol Urine Testing in Patients Taking Fexofenadine: A Tale of Two Consecutive Cases.
  Yousuf SM, Alater AM, Alabdulla M, Osman M. Yousuf SM, et al. Case Rep Psychiatry. 2023 Jan 5;2023:4370648. doi: 10.1155/2023/4370648. eCollection 2023. Case Rep Psychiatry. 2023. PMID: 36643013 Free PMC article.
• Nasal obstruction, the airway, and the athlete.
  Fisher LH, Davies MJ, Craig TJ. Fisher LH, et al. Clin Rev Allergy Immunol. 2005 Oct;29(2):151-8. doi: 10.1385/CRIAI:29:2:151. Clin Rev Allergy Immunol. 2005. PMID: 16251769 Review.
• H1 antihistamines and driving.
  Popescu FD. Popescu FD. J Med Life. 2008 Jul-Sep;1(3):262-8. J Med Life. 2008. PMID: 20108503 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Ovid Technologies, Inc.